Skip to main content
. 2016 Aug 12;8(33):54136–54148. doi: 10.18632/oncotarget.11250

Figure 1. High fractalkine/CX3CL1 expression is correlated with tumor stage and cell migration ability.

Figure 1

A. The cell migration ability of the osteoblast cell line hFOB 1.19 and the osteosarcoma cell lines MG63 and U2OS was assessed using the Transwell assay. B and D. Total mRNA and protein were collected from the indicated cell lines, and fractalkine expression was detected using qPCR, Western blotting and ELISA assay. E. The osteosarcoma cell lines MG63 and U2OS were incubated with the indicated concentrations of fractalkine for 24 h, and cell migration ability was assessed using the Transwell assay. F-G. Total mRNA and protein were collected from the indicated cell lines, and CX3CR1 expression was detected using qPCR and Western blotting. H-I. MG63 cells were transfected with CX3CR1 or negative siRNA (control) for 24 h and then incubated with fractalkine (10 ng/mL) for 24 h. Cell migration ability was analyzed using the Transwell assay. Results are expressed as the mean ± SEM of triplicate samples. A-D: *P < 0.05 compared with hFOB 1.19 cells. E–I: *P < 0.05 compared with the control group and #P < 0.05 compared with the fractalkine-treated group.